Table 3. Major adverse cardiac events of different groups.
| MACE | In-hospital (n = 621) |
Three months (n = 587) |
Six months (n = 552) |
||||||
| Low-risk (n = 405) | Control (n = 108) | Combination therapy (n = 108) | Low-risk (n = 392) | Control (n = 97) | Combination therapy (n = 98) | Low-risk (n = 365) | Control (n = 91) | Combination therapy (n = 96) | |
| Ischaemia driven MACE | 8 (2.0%) | 5 (4.6%) | 2 (1.9%)* | 15 (3.8%) | 7 (7.2%) | 4 (4.1%)* | 20 (5.5%) | 12 (13.2%) | 6 (6.3%)* |
| Cardiac death | 1 (0.2%) | 1 (0.9%) | 0 (0%) | 1 (0.3%) | 3 (3.1%) | 1 (1.0%)* | 2 (0.5%) | 4 (4.4%) | 1 (1.0%)* |
| MI | 2 (0.5%) | 1 (0.9%) | 0 (0%) | 5 (1.3%) | 1 (1.0%) | 1 (1.0%)* | 6 (1.6%) | 3 (3.3%) | 2 (2.1%)* |
| Ischaemia driven TLR | 5 (1.2%) | 3 (2.8%) | 2 (1.9%)* | 9 (2.3%) | 3 (3.1%) | 2 (2.0%)* | 12 (3.3%) | 5 (5.5%) | 3 (3.1%)* |
Data are presented as n (%). *Compared with control, P < 0.05. MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularization.